Breaks Categories: News

ThursdayMay 23, 2024 11:58 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to the announcement, this is the first-ever DehydraTECH(TM)-processed tirzepatide from Zepbound(R) to be tested in a swallowed oral format. The study is designed to evaluate a dual-action GLP-1 (glucagon-like peptide) plus GIP (glucose-dependent insulintropic peptide) in a randomized, crossover investigation that will compare injected Zepbound tirzepatide by Eli Lilly to a compound formulated, DehydraTECH-processed tirzepatide that is derived from Zepbound but in a capsule form. Test articles for the study will be manufactured…

Continue Reading

WednesdayMay 22, 2024 2:59 pm

CannabisNewsBreaks – AROYA Marks Release of 100th Episode of ‘Office Hours Live,’ Designed to Provide Cannabis Cultivation Guidance, Support and Community

AROYA, the leading cannabis cultivation platform, has reached a significant milestone for “Office Hours Live,” its popular podcast series. According to the announcement, “Office Hours Live” recently released its 100th episode, with each episode focused on providing free, science-based and expert-approved guidance on cannabis cultivation. Hosted by cannabis cultivation experts Seth Baumgartner and Jason Van Leuven, the series has had millions of views and downloads worldwide, answered more than 900 cultivator questions and featured 13 guests from various sectors of the cannabis industry; the episodes also include live question-and-answer segments where participants can interact directly with the hosts. “We created…

Continue Reading

WednesdayMay 22, 2024 2:52 pm

CannabisNewsBreaks – CWCBExpo Names Josh Kesselman as Keynote Speaker for 10th Annual Trade Show and Conference

Cannabis World Congress & Business Exposition (“CWCBExpo”), the premier East Coast trade show and conference dedicated to the legalized cannabis industry, has announced the keynote speaker for next month’s event. According to the announcement, Josh Kesselman, iconic CEO and philanthropic founder of HBI International, will provide the main address. HBI International is the company behind RAW Rolling Papers. The CWCB Expo is scheduled for June 5–6, 2024, in New York City. Kesselman will open the event, presenting on the main stage at 11 a.m. ET on June 5; his presentation, which will be styled after a fireside chat, will be hosted by…

Continue Reading

WednesdayMay 22, 2024 1:17 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received two new patent awards, bringing the company’s patent portfolio to 43 granted patents worldwide. According to the announcement, the company has been granted a patent in its patent family #21, “Compositions and Methods for Treating Hypertension.” The company noted that this is the third granted U.S. patent in this category and is regarding the company’s DehydraTECH(TM)-processed cannabidiol (“CBD”) and evidence of its ability to lower blood pressure in both acute dosing in hypertension as well as during a five-week study duration. In addition, Lexaria has received a granted patent…

Continue Reading

TuesdayMay 14, 2024 3:34 pm

CannabisNewsBreaks – Zoned Properties Inc. (ZDPY) Releases Q1 2024 Financial Results Showing 22% Revenue Growth

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, including legalized cannabis, released its financial results for Q1 2024, the period ended March 31; the company also noted recent business highlights. According to the report, financial highlights include revenues totaling $837,052 for the quarter ended March 31, 2024, compared to $688,024 million revenues for the same quarter 2023, representing an increase of 22%; net income of $96,473, or $0.01 per fully diluted share, as compared to a net loss of $309,648, or ($0.03) per fully diluted share, for the same quarter in 2023, representing…

Continue Reading

TuesdayMay 14, 2024 2:31 pm

CannabisNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company’s strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through the third quarter of fiscal year 2024; the company’s subsidiary, 1st Detect, accepting orders for the TRACER 1000 Narcotics Trace Detector (“NTD”); the TRACER 1000 being listed in the U.S. General Services Administration (“GSA”) IT…

Continue Reading

MondayMay 13, 2024 1:23 pm

CannabisNewsBreaks – CannaCon Names CannabisNewsWire, IBN as Media Partners for Upcoming 2024 Events

CannaCon, a global business-to-business (“B2B”) venue for cannabis businesses, marijuana entrepreneurs, investors and community partners, has selected CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of more than 60 brands powered by IBN, as the Official NewsWire for its upcoming CannaCon West Albuquerque; the event is slated for May 17–18, 2024. In addition, CannabisNewsWire and IBN will partner with CannaCon as official media partners for several upcoming events, including Midwest conferences scheduled on Aug. 16–17, 2024, in Albuquerque and on Oct. 3–4, 2024, in Cleveland. According to the announcement, IBN and CNW will use their comprehensive portfolio of communications…

Continue Reading

WednesdayMay 08, 2024 2:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database…

Continue Reading

MondayMay 06, 2024 3:15 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…

Continue Reading

WednesdayMay 01, 2024 3:50 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Responds to Announcement Rescheduling of Marijuana by DEA

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a holding company focused in the cannabis and agricultural technology sectors, released an official reaction to the “historic milestone” in the cannabis industry as the U.S. Drug Enforcement Administration (“DEA”) moves to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (“CSA:). The reclassification was fueled by a recommendation from the U.S. Department of Health and Human Services and represents a notable change in U.S. drug policy. According to the announcement from MedCana, cannabis has been unjustly categorized as a Schedule I substance alongside heroin and LSD for…

Continue Reading